Related references
Note: Only part of the references are listed.Pharmacology and pharmacokinetics of imatinib in pediatric patients
Meinolf Suttorp et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial
Lia Gore et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia
Thomas Ernst et al.
LEUKEMIA (2018)
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial
Meinolf Suttorp et al.
LEUKEMIA (2018)
Transition and transfer of childhood cancer survivors to adult care: A national survey of pediatric oncologists
Lisa B. Kenney et al.
PEDIATRIC BLOOD & CANCER (2017)
Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents
Frederic Millot et al.
HAEMATOLOGICA (2017)
Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents
Frederic Millot et al.
HAEMATOLOGICA (2017)
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Remy B. Verheijen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Pediatric chronic myeloid leukemia is a unique disease that requires a different approach
Nobuko Hijiya et al.
BLOOD (2016)
Leukostasis in Children and Adolescents with Chronic Myeloid Leukemia: Japanese Pediatric Leukemia/Lymphoma Study Group
Hidemitsu Kurosawa et al.
PEDIATRIC BLOOD & CANCER (2016)
Moving treatment-free remission into mainstream clinical practice in CML
Timothy P. Hughes et al.
BLOOD (2016)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A. Hochhaus et al.
LEUKEMIA (2016)
Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia
Jill Samis et al.
PEDIATRIC BLOOD & CANCER (2016)
Optimal management for pediatric chronic myeloid leukemia
Akihiko Tanizawa
PEDIATRICS INTERNATIONAL (2016)
Management of pregnant chronic myeloidleukemia patients
Elisabetta Abruzzese et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Lauren Caldemeyer et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2016)
Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?
David Gurrea Salas et al.
ANNALS OF HEMATOLOGY (2015)
Managing pregnancy in chronic myeloid leukaemia
Renuka Palani et al.
ANNALS OF HEMATOLOGY (2015)
Chronic Myeloid Leukemia in Children Clinical Findings, Management, and Unanswered Questions
Nobuko Hijiya et al.
PEDIATRIC CLINICS OF NORTH AMERICA (2015)
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
Peter Valent et al.
BLOOD (2015)
Managing children with chronic myeloid leukaemia (CML) Recommendations for the management of CML in children and young people up to the age of 18 years
Josu de la Fuente et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies
Jose O. Aleman et al.
ENDOCRINE-RELATED CANCER (2014)
Supporting Adolescents and Young Adults With Cancer Through Transitions: Position Statement From the Canadian Task Force on Adolescents and Young Adults With Cancer
Krista L. Wilkins et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2014)
Imatinib Cessation in Children and Adolescents With Chronic Myeloid Leukemia in Chronic Phase
Frederic Millot et al.
PEDIATRIC BLOOD & CANCER (2014)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia
Manuela Krumbholz et al.
GENES CHROMOSOMES & CANCER (2012)
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial
Francois Guilhot et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy
Naveen Pemmaraju et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors
Antoine Adenis et al.
MEDICAL ONCOLOGY (2012)
Leukocyte Depletion by Therapeutic Leukocytapheresis in Patients with Leukemia
Kristina Hoelig et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2012)
Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial
Frederic Millot et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Higher Dose Imatinib for Children With De Novo Chronic Phase Chronic Myelogenous Leukemia: A Report From the Children's Oncology Group
Martin A. Champagne et al.
PEDIATRIC BLOOD & CANCER (2011)
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The blast phase of chronic myeloid leukaemia
Richard T. Silver
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia
Ronald Adler et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia
Simona Soverini et al.
CLINICAL CANCER RESEARCH (2006)
Safety of live-virus vaccines for children with immune deficiency
Karlen E. Luthy et al.
JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia
F Millot et al.
PEDIATRICS (2005)
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study
MA Champagne et al.
BLOOD (2004)
Share Paper
